📞 
— free, 24/7
— free, 24/7 — free, 24/7| Dosage | Package | Price per Dose | Price | |
|---|---|---|---|---|
| 3ml | 6 bottles | £32.64 | £195.81 Best Price Popular | |
| 3ml | 4 bottles | £34.04 | £136.16 | |
| 3ml | 3 bottles | £34.89 | £104.65 | |
| 3ml | 2 bottles | £37.13 | £74.27 | |
| 3ml | bottle | £41.63 | £41.63 |
Disclaimer: This information is intended to support discussion with a healthcare professional. It does not replace personalised medical advice.
Latisse (bimatoprost) is a prostamide/prostaglandin analogue used to promote eyelash growth. It is a topical ophthalmic solution formulated to stimulate eyelash length, fullness, and darkness where eyelashes are insufficient. The medication belongs to a class of prostaglandin-like agents that affect ocular tissues to influence hair growth along the lash margin.
The primary therapeutic aim is to improve the appearance of sparse or short eyelashes by increasing their length and perceived fullness. It is not intended for use on other hair on the face or body, nor for general cosmetic hair growth elsewhere. If confusion arises about the correct use, the official patient leaflet should be consulted or a pharmacist or clinician contacted for clarification.
In the UK context, Latisse may require a prescription depending on local rules; availability can vary by setting. If a prescription is necessary, the prescriber will assess suitability before dispensing. Additional information may be provided in the product insert or by the pharmacist at point of dispensing.
The product is applied topically to the upper eyelid margin using a supplied applicator. Application is typically performed once daily, under medical guidance, with careful attention to technique to minimise spread to the eye surface or surrounding skin. If there is any doubt about whether the product is appropriate, a healthcare professional should be consulted.
Clinical use requires an assessment of ocular surface health and eyelid skin condition. If a new eye symptom develops or existing symptoms worsen, medical review is advised promptly. Check the official leaflet or consult a pharmacist or clinician if questions arise about indications or use.
The following information explains safety considerations, administration, and practical aspects to support informed, precautionary use in routine care.
Known hypersensitivity to bimatoprost or any component of the formulation constitutes a contraindication. If a history of allergic reaction to prostaglandin analogues is present, avoidance is advised until a clinician has reviewed alternatives. Reactions may include swelling, itching, or redness of the eyelids or eyes.
Active ocular infection or significant eye inflammation is a reason to withhold treatment until resolved and a clinician has re-evaluated suitability. Initiation during an active infection could worsen symptoms or complicate healing.
Severe eyelid or periocular skin disease should prompt caution. Inflammation or skin breakdown at the application site may be aggravated by topical prostaglandin analogues. If eyelid skin disease is present, seek clinician input prior to use.
Pregnant individuals should discuss use with a clinician before starting therapy. Breastfeeding status should also be disclosed, as safety in lactation has not been established. If pregnancy is possible or there is any chance of conception, a cautious approach is recommended, and discontinuation may be advised by a clinician depending on risk versus benefit.
Contact lens users should not rely on the product while wearing lenses. If contact lenses are worn, remove lenses before application and reinsert only after an appropriate interval, as advised by the prescribing clinician. If there is uncertainty, discuss contact lens use with a pharmacist or clinician before starting treatment.
Allergic or hypersensitivity reactions to preservatives or other formulation ingredients may necessitate avoidance. If swelling, redness, or itch persists, cease use and seek professional advice promptly.
Pigment changes around the eye are a recognised potential outcome with prostaglandin analogue therapies. Darkening of the iris (eye colour) or the eyelid skin can occur and may be permanent. Monitoring for skin colour change and iris colour change is advised, and any progression should be discussed with a clinician.
Eyelid or eye irritation, redness, or itchiness can occur, particularly in the early weeks of treatment. If these symptoms persist or worsen, discontinue use and seek medical advice. Chronic irritation could indicate a local issue requiring examination or alternative therapy.
Thorough hand hygiene and careful cleaning of the applicator are important to minimise contamination risks. Avoid contact with the eye surface beyond the intended application area to reduce adverse effects. If there is accidental spillage into the eye, rinse gently with clean water and seek professional advice if symptoms persist.
Infrequent systemic effects have been reported with topical prostaglandin analogues, though such effects are uncommon. Any new systemic symptoms—such as persistent headaches, dizziness, or weakness—should be discussed with a clinician to determine whether they are related to treatment or another condition.
Duration of therapy and treatment response vary between individuals. If eyelash growth does not occur or if improvement is not satisfactory after an extended period, a clinician should be consulted to review continued use, alternative options, or dosing strategy. Additional monitoring may be required in patients with underlying ocular conditions or those taking other eye medications.
Regular review of ocular health is recommended during therapy, particularly for individuals with existing glaucoma risk or ocular surface disease. Do not redefine treatment plans solely based on personal experience; seek professional guidance for ongoing safety assessments and continuation decisions.
Common eye-related effects include mild eye irritation, itching, or redness after application. Some users may notice a sensation of dryness or a foreign body feeling in the eye. These symptoms are usually transient and resolve with continued use or after stopping the product.
Pigment-related changes around the eye, including darker skin at the eyelid margin, may occur. Iris colour changes or darkening of the coloured part of the eye are possible and may be permanent. Patients should be counselled on this possibility as part of informed consent prior to initiation.
Other ocular changes such as eyelid droop (ptosis) or eyelid swelling can occur, though these are less common. If vision becomes blurred or if irregular eyelid function develops, seek urgent medical evaluation. Do not ignore new or worsening ocular symptoms.
Uncommon but potentially serious ocular events include conjunctival redness, corneal irregularities, or eyelash shedding. If new eye symptoms arise, discontinue use and arrange review with a clinician to determine causality and next steps.
Discolouration or darkening of skin around the application area may persist after use. Changes in texture or thickness of the eyelid skin might be observed in some individuals. If cosmetic changes become a concern, discuss with a clinician about continuation or cessation of therapy.
Local skin irritation at the application site can occur, including itching or dermatitis-like symptoms. Avoid scratching or rubbing the area and seek medical advice if irritation persists or worsens.
Headache or light-headedness has been reported in some users. Such symptoms are typically mild and transient, but persistence warrants medical discussion to rule out alternative causes or to reassess therapy.
Systemic side effects are possible but uncommon with topical application. Any unusual symptoms such as dizziness, fatigue, or malaise should be evaluated in the context of overall health and concomitant medications.
Concomitant use of other eye drops or ophthalmic medications may affect local tolerability or ocular surface health. A clinician may advise spacing administrations by several minutes between different products to minimise interaction at the ocular surface. Inform the prescribing clinician of all eye medicines being used.
Patients with glaucoma or ocular hypertension who already use intraocular pressure–lowering therapy should have a careful review before starting Latisse. Combined use can alter the risk-benefit profile and may require monitoring of intraocular pressure and ocular surface status.
No broadly established interactions with common OTC medicines or herbal products have been documented in routine practice. However, inform a pharmacist about all substances used, particularly those with known ocular or dermatologic effects, to ensure no additive irritation or unexpected reactions occur.
There are no routinely reported interactions with caffeine-containing beverages; still, avoid any combination that might predispose to dehydration or ocular surface dryness if eye symptoms arise.
Food intake is not expected to have a direct impact on the effect of Latisse when applied as directed. Alcohol consumption is not reported to have a direct interaction with the topical solution, but excessive alcohol use can worsen dehydration and dryness of the ocular surface, potentially increasing discomfort during treatment.
Licence and regulatory status varies by country. If proceeding with a private prescription or self‑purchase, confirm local guidance with a pharmacist or clinician about possible interactions with any other prescribed medicines or supplements.
The safety of Latisse in pregnancy has not been established. A cautious approach is advised, and treatment should be discussed with a clinician if pregnancy is possible or if pregnancy occurs during use. Decision-making should consider potential risks and benefits for both the patient and the fetus.
Sensitivity regarding use during breastfeeding exists due to incomplete data on systemic absorption and transfer into breast milk. A clinician should be consulted to determine whether continuation, modification, or cessation is appropriate during lactation.
Teligence regarding safety and efficacy in children is limited. The product is not routinely indicated for pediatric use, and a clinician's assessment is required for any consideration in younger individuals. Special monitoring may be necessary if use is deemed appropriate by a clinician.
Age alone does not mandate a dosing adjustment for topical agents; however, older individuals may have concurrent ocular surface disease or systemic conditions that require careful assessment. A clinician should determine suitability and monitor for adverse reactions closely in this population.
Administration requires careful application to the upper eyelid margin using the supplied applicator. The applicator should be used exactly as directed to avoid unintended contact with the eye surface or lower lashes. If there is doubt about technique, request practical guidance from a pharmacist or clinician.
Prior to application, hands should be washed, and any contact lenses should be removed if applicable. Lenses may be reinserted after the recommended interval. Keep the applicator clean and avoid sharing devices with others to minimise infection risk.
Avoid applying the solution to other parts of the face or skin. Do not apply near the globe of the eye or to the lower eyelid margin. Allow a short period for drying before engaging in activities such as blinking or closing the eye fully to prevent inadvertent transfer to the eye surface or surrounding skin.
Storage should be in line with the product label: maintain the bottle in its original container, protect from light, and keep at room temperature away from heat sources. Do not use beyond the expiry date, and discard any unused portion according to local waste guidance. If the container is damaged or the solution appears cloudy or discoloured, discontinue use and seek guidance from a pharmacist or clinician.
Missed doses should be resumed with the next scheduled application as directed by a clinician. Do not attempt to 'make up' a missed dose by applying extra product. If more than one dose is missed, seek professional advice to determine the safest course of action.
General safety framing: the following questions cover common safety concerns and practical decisions that patients frequently raise. The answers emphasise cautious use and seeking professional input for uncertainties or adverse events.
One important note: Do not rely on these responses as a substitute for personalised medical advice. If there is any doubt about safety or suitability, consult a clinician or pharmacist before continuing.
Contact lenses can be worn in most cases, but lenses should be removed before applying the product. Reinsert lenses only after the recommended interval, and verify with a clinician whether any adjustments are needed based on ocular health and eye surface condition.
Different eye drops may interact at the ocular surface, potentially affecting comfort or efficacy. A clinician may advise spacing administrations by several minutes and to use products in a specific order. If any new or worsening symptoms occur, seek medical advice promptly.
Safety in pregnancy has not been established. A clinician will weigh potential risks and benefits. If pregnancy occurs during use or if pregnancy is planned, discuss options with a healthcare professional before continuing therapy.
Iris colour changes can occur with use and may be permanent. A clinician should explain the likelihood, reversibility, and implications of pigment changes before treatment begins.
Response time varies between individuals and is influenced by baseline lash characteristics and adherence to application instructions. If no meaningful improvement is observed after a reasonable period, a clinician may reassess therapy and consider alternatives.
Persistent or worsening redness or irritation warrants discontinuation of use and medical assessment. If symptoms are severe, seek urgent medical advice. Do not continue treatment if symptoms indicate an adverse reaction or infection.
Rare but potentially serious effects can include significant swelling, vision disturbances, or severe allergic reactions. Seek urgent medical help if any sudden changes in vision, severe eye swelling, or signs of an allergic reaction occur.
Discontinuation is possible at any time, but the cosmetic effect may diminish over weeks to months after stopping. A clinician can provide guidance on an appropriate plan for cessation and any follow-up care.
No direct interaction is commonly reported between alcohol and the topical use of Latisse. However, excessive alcohol use may contribute to dehydration or ocular surface dryness, which can influence comfort during treatment.
Blood tests are not routinely required for topical ocular therapy with Latisse. If any systemic symptoms arise or if there is a reason to suspect a systemic reaction, a clinician may advise appropriate investigations.
Cosmetic products worn near the eye are generally compatible, but avoid applying products to the eyelid margin that could irritate the skin or ocular surface. If irritation occurs, consult a clinician to determine whether adjustments are needed.
Use in children is not routinely recommended without specialist assessment. A clinician must determine suitability and safety for younger patients, with careful consideration of ocular health and cosmetic goals.
If a drop enters the eye unintentionally, rinse gently with clean water and monitor for irritation. If discomfort, redness, or vision changes persist, seek medical advice promptly to determine whether further action is required.
cosmetic improvements tend to wane over time after stopping use, with lashes returning gradually toward baseline. The rate of regression varies between individuals and may depend on lash growth cycles and other factors.
Official product information and patient leaflets provided by manufacturers are primary sources for safety and administration guidance. The UK Medicines and Healthcare products Regulatory Agency (MHRA) provides regulatory information about medicines and devices.
National Health Service (NHS) materials offer general safety guidance for topical ocular therapies and can be a helpful reference point for patients seeking non‑prescription information or pharmacovigilance updates.
British National Formulary (BNF) entries and accompanying pharmacist guidance contribute to evidence-based considerations for prescribing and monitoring prostaglandin analogue therapies used around the eye.
Clinical guidance and NICE recommendations may address broader contexts of eyelash growth therapies, cosmetic dermatology, and ocular surface health. In cases of uncertainty, consult a pharmacist or clinician for interpretation in the local regulatory framework.
14–21 days. Free from £150.05 .
5–9 days. £22.51
−10% when paying with cryptocurrency.
−10% on all repeat orders.
All orders are packed in neutral, unbranded boxes with no product name on the outside.